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Abstract. Solid dispersions (SDs) are an approach to increasing the water solubility and bioavailability of
lipophilic drugs such as ursolic acid (UA), a triterpenoid with trypanocidal activity. In this work, Gelucire
50/13, a surfactant compound with permeability-enhancing properties, and silicon dioxide, a drying
adjuvant, were employed to produce SDs with UA. SDs and physical mixtures (PMs) in different drug/
carrier ratios were characterized and compared using differential scanning calorimetry, hot stage micros-
copy, Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), particle size, water
solubility values, and dissolution profiles. Moreover, LLC-MK2 fibroblast cytotoxicity and trypanocidal
activity evaluation were performed to determine the potential of SD as a strategy to improve UA efficacy
against Chagas disease. The results demonstrated the conversion of UA from the crystalline to the
amorphous state through XRD. FTIR experiments provided evidence of intermolecular interactions
among the drug and carriers through carbonyl peak broadening in the SDs. These findings helped explain
the enhancement of water solubility from 75.98 μg/mL in PMs to 293.43 μg/mL in SDs and the faster drug
release into aqueous media compared with pure UA or PMs, which was maintained after 6 months at
room temperature. Importantly, improved SD dissolution was accompanied by higher UA activity against
trypomastigote forms of Trypanosoma cruzi, but not against mammalian fibroblasts, enhancing the
potential of UA for Chagas disease treatment.
KEY WORDS: Chagas disease; Gelucire 50/13; solid dispersions; solvent evaporation method; ursolic
acid.
INTRODUCTION
Many potential drug candidates never reach the market
because of low bioavailability, which can be a consequence of
low solubility or limited gastrointestinal tract permeability.
Methods for overcoming this problem include size reduction,
surfactant use, salt formation, pH adjustment, cyclodextrin
complex formation, pro-drug formulations, and liposome
preparation (1). Among commonly utilized methods, one of
the most efficacious is the use of solid dispersions (SDs),
which are defined as molecular or amorphous drug mixtures
with low water solubility and hydrophilic carriers that improve
the drug dissolution profile (2,3).
These enhanced dissolution profiles are attributed to par-
ticle size reduction, reduced agglomeration, improved wetta-
bility, and drug conversion from a crystalline structure to a
more soluble, amorphous form (4). The use of a hydrophilic
polymer enhances drug dissolution, which makes its selection
critical for developing a successful solid dispersion. Polyethyl-
ene glycols and polyvinylpyrrolidones are among the polymers
that are most frequently employed as carriers in solid disper-
sions, but polymers with inherent surfactant properties improve
the dissolution properties of many lipophilic drugs. This class of
solid dispersion polymers also has the advantage of avoiding
drug recrystallization, a stability problem that is commonly as-
sociated with solid dispersions. Recrystallization can be pre-
vented with use of surfactants such as Poloxamers and
Gelucires, which reportedly enhance oral bioavailability in vivo
(5,6). Gelucires belong to a family of vehicles that are derived
from mixtures of mono-, di-, and triglycerides and polyethylene
glycol fatty acid esters. Gelucires with different properties are
available, including various HLB values (1–18) and melting
points (33–70°C) (5). They have successfully been used as car-
riers in solid dispersions of indomethacin (7), nifedipine (8),
glibenclamide (9), and diclofenac (10). Gelucire enhances bio-
logical membrane penetration and could thus increase the bio-
availability of drugs displaying low oral absorption (11).
In this work, solid dispersions with Gelucire 50/13 and
silicon dioxide, a drying adjuvant, have been generated as an
approach to enhance the lipophilic molecule ursolic acid (UA)
dissolution profile, for which low bioavailability limits its ther-
apeutic potential (12). Ursolic acid is a pentacyclic triterpe-
noid (13) that possesses anti-inflammatory (14), anti-cancer
(15), hepatoprotective (16), and trypanocidal (17) pharmaco-
logical properties. Among these, the trypanocidal activity is of
particular interest to our research group because we want to
1 Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of
São Paulo, Ribeirão Preto, Avenida do Café s/n, 14040-903 Ribeirão
Preto, São Paulo, Brazil.
2 To whom correspondence should be addressed. (e-mail:
jmarchet@usp.br)
AAPS PharmSciTech, Vol. 13, No. 4, December 2012 (# 2012)
DOI: 10.1208/s12249-012-9868-2
14361530-9932/12/0400-1436/0# 2012 American Association of Pharmaceutical Scientists
improve Chagas disease treatment. Chagas disease is caused
by Trypanosoma cruzi and is a life-threatening pathology
affecting approximately 15 million people, mostly in Latin
America. The current treatment, 2-nitroimidazole benznida-
zole (Rochagan®), displays limited efficacy in the chronic
disease phase of Chagas and is toxic to patients. Therefore,
other drugs must be investigated that are more efficient and
less toxic (18). Our group has previously developed solid
dispersions employing polyethylene glycol 6000 and Polox-
amer 407 as carriers; however, despite an improvement in
the ursolic acid dissolution profile in Poloxamer 407-prepared
products, the in vitro trypanocidal activity was not enhanced,
which could be attributed to low drug penetration in the
parasite cell. Therefore, we studied the lipid carrier Gelucire
50/13 in solid dispersion preparation (Fig. 1).
Solid dispersions and physical mixtures (PMs) in different
drug and carrier ratios were characterized and compared us-
ing differential scanning calorimetry (DSC), hot stage micros-
copy (HSM), Fourier transform infrared spectroscopy (FTIR),
X-ray diffraction (XRD), particle size, water solubility values,
and dissolution profiles. Moreover, cytotoxicity against LLC-
MK2 fibroblasts and trypanocidal activity were evaluated to
determine the potential of solid dispersion to improve ursolic
acid efficacy against Chagas disease.
MATERIALS AND METHODS
Materials
UAwas purchased from Idealfarma (Brazil); high-perfor-
mance liquid chromatography (HPLC) grade acetonitrile and
methanol were purchased from Merck (Germany). Gelucire
50/13 was a kind gift from Gattefossé (France).
Methods
Solid Dispersion and Physical Mixture Preparation
Solid dispersions containing the drug, Gelucire, and sili-
con dioxide in ratios of 1:0.6:0.4 (SD 001), 1:3:1 (SD002), 1:7:2
(SD003), and 1:15:4 (SD004) (w/w/w) were prepared by the
solvent method. The drug and carriers were dissolved in
methanol (10%w/v), and the solvent was subsequently evap-
orated at room temperature while stirring. The products were
then stored in an oven at 40°C for 24 h to ensure complete
methanol evaporation, followed by pulverization with a
mortar and pestle. The PMs were prepared by grinding the
drug and carriers together using a mortar and pestle.
Solid Dispersion and Physical Mixture Characterization
Fourier Transform Infrared Spectroscopy
FTIR analyses were conducted using a Shimadzu IRPres-
tige-21 instrument. The samples were previously ground and
mixed thoroughly with potassium bromide. The potassium
bromide disks were prepared by compressing the powders in
a hydraulic press. Scans were obtained at a resolution of
2 cm−1 from 4,000 to 400 cm−1 (Fig. 2).
Differential Scanning Calorimetry
DSC measurements were performed using a Shimadzu
DSC-50 instrument. Samples were placed in aluminum pans
and heated from 30°C to 330°C at a rate of 10°C/min. Cali-
bration was performed using indium and n-octadecane as
reference materials.
Hot Stage Microscopy
Sample HSM was conducted with a TMSSG 600
(Linkam) instrument assembled on an Axioplan 2 Image
(Zeiss) microscope equipped with an Axiocam HRC camera
(Zeiss). A small amount (2–4 mg) of sample was placed on a
glass slide with a cover slip and heated at a rate of 10°C/min.
Changes in sample morphology were photographed.
X-ray Diffraction
X-ray diffraction measurements were performed using a
Siemens/D5005 instrument with a copper anode operating
under CuK radiation (1.5406 Å, 40 kV, and 30 mA). Patterns
were obtained using a step width of 0.05°/s from 2° to 50° at
room temperature on a 2Ө scale.
Drug Content Determination
The amount of UA in the PMs and SDs was deter-
mined by HPLC, following a method previously devel-
oped and validated by our group (19). The equipment
used was a Shimadzu HPLC equipped with an LC-
10ADVP pump, a SPD-10A VP UV detector, and a model
CR6-A integrator. The analyte was eluted with a mobile
phase composed of acetonitrile/water (88:12, v/v) at a 1.0-
mL/min flow rate using a 20-μL total injection volume.
UV detection was performed at 203 nm, and separation
was accomplished using a C18 reverse-phase column
(LiChrospher® (Merck), 250×4 mm (5 μm)) at room
temperature (25°C). To analyze UA content, SD and PM
samples containing 2.5 mg UA were dissolved in 100 mL
acetonitrile and filtered through a 0.45-μm membrane be-
fore HPLC analysis (n03).
Particle Size
Particle size was measured with a Beckman Coulter LS 13
320 laser diffraction particle size analyzer.Fig. 1. Chemical structure of ursolic acid
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Solid Dispersion and Physical Mixture Evaluation
Water Solubility
Pure UA, PM, or SD solubility in water was measured by
adding the drug in excess (10 mg) to 10 mL distilled water with
magnetic stirring (300 rpm) at 25°C for 24 h. Samples were
filtered (0.45 μm), dissolved in acetonitrile (1:10, w/v), and
analyzed by HPLC (n03).
Dissolution Profile
Dissolution studies were conducted on an SR8 Plus Han-
son Corporation instrument (Chatsworth, CA, USA). A sam-
ple amount equivalent to 7.5 mg UA was added to 900 mL
phosphate buffer at pH 6.8 containing 1% sodium lauryl sul-
fate (37°C±0.2°C), and the mixture was stirred with a paddle
at 75 rpm. At predetermined times, 1-mL aliquots were with-
drawn, replaced by fresh media, and filtered (0.45 μm) before
dilution (1:10, v/v) and HPLC analysis.
Cytotoxicity
SD and PM containing 5% drug were evaluated for
cytotoxicity on LLC-MK2 fibroblasts with the MTT meth-
od (20). Briefly, LLCMK2 cells (1×106/mL) were cultured
in 96-well plates containing products at the following
dilutions: 8, 32, 128, 256, and 500 μM. Plates were
incubated in a CO2 incubator at 5% CO2 and 37°C for
24 h. Ten-microliter MTT solution (5 mg/mL) was then
added to each well, and plates were incubated for 4 h.
Then, 100 μL of acid isopropyl was added, followed by
room temperature incubation for 1 h. The plate was read
on a spectrophotometer at 595 nm.
Trypanocidal Bioassay
SD and PM containing 5% drug were evaluated for
trypanocidal activity using infected blood according to a
method described by Grael and collaborators (21). Briefly,
Swiss albino mice that had been infected with the T. cruzi
‘Y’ strain were used to provide trypomastigote forms.
Infected blood was collected at the parasitemic peak
(7 days after infection; 1×106 parasites/mL) through
cardiac puncture using heparin as an anticoagulant in a
7:3 blood/anticoagulant ratio. The assays were performed
in 96-well microplates; aliquots of the PM004 and SD004
products were added to the diluted blood to give final
concentrations of 8, 32, 128, and 256 μM. The microplates
were kept stirring at 4°C for 24 h, and parasite number
was determined according to Brener (22). All of the
bioassays were performed in triplicate. The results are
presented as the lysis percentages of T. cruzi trypomastigote
forms, representing trypanocidal activity. The inhibitory
concentration (IC50) was calculated with a sigmoidal dose–
response curve.
Fig. 2. FTIR analyses of UA, silicon dioxide, Gelucire, SDs (a), and PMs (b) containing 50%, 80%,
90%, and 95% (w/w) of the carrier, from top to bottom
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RESULTS
Solid Dispersion and Physical Mixture Characterization
Fourier Transform Infrared Spectroscopy
UA has characteristic bands that should be highlighted.
The band at approximately 1,650 cm−1 corresponds to the UA
carbonyl group, and the band at approximately 3,400 cm−1 was
attributed to the UA hydroxyl group. Carbonyl and hydroxyl
groups are also present in the Gelucire chemical structure, and
the corresponding bands were observed in its spectrum.
Silicon dioxide exhibits two characteristic bands, one at
approximately 1,000 cm−1, which is attributed to a S0O
stretching vibration, and another at approximately
3,400 cm−1, which is associated with O-H stretching
vibrations of water molecules adhered to its highly
hydrophilic surface. The PM and SD spectra contained
carrier and drug in different proportions and exhibited all of
the previously mentioned bands, confirming the presence of
drug and carriers in the products. The carbonyl groups
appeared as sharp bands in the PMs and were less intense in
the SDs.
Differential Scanning Calorimetry
As observed in Fig. 3, the DSC curve of pure UA has an
exothermic peak at approximately 200°C, which is related to a
crystallization event, and an endothermic peak at approxi-
mately 280°C, which is related to a melting process. Gelucire
shows a broad endotherm at approximately 45°C, which is also
related to its melting, whereas silicon dioxide does not present
an endotherm because of its high melting temperature. In the
PM DSC curves, the Gelucire endotherm peak is observable
for all formulations, but the UA peak can only be identified in
the PMs containing 50% or 20% drug. SD curves containing
50% UA attributed the peak to the drug but not the Gelucire
endotherm. The product containing 20% drug exhibited peaks
for both the carrier and the drug, but the UA peak was
reduced. The SDs prepared with 5% and 10% drug had
DSC curves that were identical to the PMs, in which only the
peak corresponding to Gelucire was present.
Hot Stage Microscopy
The HSM observation in Fig. 4 shows a thermal event at
approximately 200°C for UA, both as the pure drug and in the
PM, in which small needle-like crystals appear before melting
completely. This phenomenon is not observed in Gelucire,
which melts at approximately 45°C, nor is it observed in the
SD containing 95% carrier.
X-ray Diffraction
The UA diffraction pattern in Fig. 5 reveals three char-
acteristic peaks at 6°, 8°, and 15°. Gelucire had two apparent
peaks at 19° and 23°. The other carrier, silicon dioxide, did not
exhibit any diffraction peaks in the range examined. The PMs
diffraction patterns contain peaks corresponding to both UA
and Gelucire that are proportional to their concentrations in
Fig. 3. DSC analyses of UA, silicon dioxide, Gelucire, PMs (a), and SDs (b) containing
50%, 80%, 90%, and 95% (w/w) of the carrier, from top to bottom
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the mixture. The pattern was different for the SDs. In the SDs
containing 50% drug, peaks attributed to the drug at 8° and
15° can be identified, but they are broadened compared with
the pure drug or with the PM. Additionally, the Gelucire X-
ray peaks disappeared. The Gelucire peaks were present for
the other SDs, whereas the UA peaks are progressively
smaller and almost disappear in the product containing 5%
drug. PMs containing 5% UA displayed peaks corresponding
to the drug after storage at room temperature after 6 months,
whereas the same peaks were not present in SDs containing
the same drug load.
Drug Content Determination
Results in Table I show UA content as a percentage of
the total amount added to the PMs and SDs, which ranged
from 88.79% for PM002 to 109.33% for PM001.
Particle Size
Table II shows the results of UA particle size, SDs, and
PMs in different drug/carrier ratios. The values ranged from
59.38 μm for SD004, which was prepared with 5% UA, to
Fig. 4. HSM photomicrographs at 25°C (a) and 200°C (b) of UA, Gelucire, PM, and SD
containing 95% (w/w) of the carrier, from top to bottom
1440 Eloy et al.
115.70 μm for SD001, which was prepared with 50% UA
(Fig. 6).
Solid Dispersions and Physical Mixture Evaluation
Water Solubility
The UA solubility values in PMs and SDs for different
carrier to drug ratios are shown in Fig. 7. UA solubility is
increased in systems containing higher percentages of the
carrier. The average UA solubility values in micrograms per
milliliter are 2.12, 11.49, 22.62, and 75.98 for PMs containing
50%, 80%, 90%, and 95% of the carrier, respectively, and
5.49, 26.08, 79.97, and 293.43 for SDs containing 50%, 80%,
90%, and 95% of the carrier, respectively.
Drug Release
The UA dissolution profile as a pure drug in PMs and in
SDs for different drug/carrier loads are represented in Fig. 7.
When dissolved in phosphate-buffered medium containing
1% sodium lauryl sulfate, pure UA has a dissolution profile
similar to that of its PMs; after 4 h, approximately 15% of the
drug is dissolved. However, the SDs dissolved faster compared
Fig. 5. X-ray analyses of UA, silicon dioxide, Gelucire, PMs (a), and SDs (b) containing 50%, 80%,
90%, 95%, and 95% (w/w) after 6 months at room temperature of the carrier, from top to bottom
Table I. UA Content Determination (in Percent) of the Amount
Labeled in PMs and SDs in Different Drug/Carrier Loads
Product UA content (%)
PM001 109.33±3.51
PM002 88.79±2.58
PM003 90.25±1.25
PM004 95.98±1.56
SD001 89.79±3.28
SD002 90.18±4.85
SD003 104.56±3.96
SD004 91.16±0.97
PM004 after 6 months 93.85±2.47
SD004 after 6 months 90.03±3.02
UA ursolic acid, PM physical mixture, SD solid dispersion
Table II. Particle Size of UA, SDs, and PMs
Product Particle size (μm)−D90
UA 79.03±27.80
PM001 94.68±34.14
PM002 91.84±32.95
PM003 87.28±31.66
PM004 103.3±35.70
SD001 115.70±39.44
SD002 99.42±36.49
SD003 114.90±38.76
SD004 59.38±21.03
UA ursolic acid, PM physical mixture, SD solid dispersion
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with the PMs. The highest UA dissolution enhancement was
achieved with the formulation containing 95% carrier
(SD004), which dissolved approximately 80% after 3 h. The
observed behavior was maintained after 6 months of storage
for products containing 5% UA.
Cytotoxicity
Cytotoxicity was evaluated for products containing 5%
UA, SD004, and PM004. The results presented in Fig. 8 dem-
onstrate that 100% cellular viability was maintained for 8, 32,
128, and 256 μM drug concentrations.
Trypanocidal Activity
In vitro trypanocidal assay results are shown in Table III.
The 250-μM UA concentration provoked the highest T. cruzi
Y strain lysis for both the PM (33.62±1.40) and the SD (48.27
±4.20). Furthermore, the SD displayed higher trypanocidal
activity than the PM, displaying an IC50 of 219.2 and
396.7 μM, respectively
DISCUSSION
There is evidence that UA bioavailability is limited by
permeability because its isomer, oleanolic acid, occupies class
IV in the Biopharmaceutics Classification System (23). There-
fore, drug solubility enhancement and faster dissolution may
not be sufficient to increase UA bioavailability. To address to
this problem, a formulation containing a penetration enhancer
could be developed, which may increase UA cell membrane
permeability and thus enhance trypanocidal activity. In previ-
ous studies, our group tested SDs containing Poloxamer 407,
which is a polymeric surfactant that has been described as a
permeability enhancer (24). However, despite the observed
enhancement in UA dissolution, Poloxamer 407 in SDs did
not improve UA trypanocidal activity, most likely because of
the low intrinsic ability of Poloxamer 407 to favor parasite cell
entry of the highly lipophilic UA.
In this work, our group studied Gelucire 50/13, which is a
member of a different surfactant carrier family that has been
described as a penetration enhancer, a characteristic attribut-
ed to its surfactant and lipid nature. Lipid surfactants such as
Gelucire reportedly cause cell membrane polar defects, thus
changing their physical properties and making them more
permeable (25,26). SDs prepared with Gelucire, however,
are usually sticky and tacky. Thus, silicon dioxide was used
as an excipient in the Gelucire-based SD products, as reported
by Chauhan and collaborators (9), who studied glibenclamide
SDs using Gelucire and silicon dioxide as carriers. In addition
to imparting good flow to the powder, silicon dioxide has
surface silanol groups that are available for hydrogen bonding
that potentially interact with the drug, causing faster dissolu-
tion by improving drug particle wettability (27).
Products prepared with 5%, 10%, and 15% (w/w) silicon
dioxide had a sticky consistency and thus could not be milled
to produce a dry and flowable powder. Only the SD prepared
with 20% (w/w) Gelucire resulted in a dry and fragile mass
that was milled, producing a homogenous drug powder that
was then characterized. This is important from an industrial
Fig. 6. Determination of the aqueous solubility of UA in PMs and
SDs with various ratios of carrier to drug
Fig. 7. Dissolution profile of UA as a pure drug, in PMs and in SDs determined in a phosphate-
buffered medium containing 1% sodium lauryl sulfate
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perspective because pulverization is one of the most problem-
atic steps during the industrial manufacturing process (28).
Moreover, the solvent method employed produced homoge-
nous dry powders in which drug content was between 89.79
and 104.56 (p/p) of the UA amount added to the products
(Table I), indicating that the process enabled SD manufactur-
ing with no appreciable losses.
Intermolecular interactions such as hydrogen bonding
between the drug and the carrier can be important for enhanc-
ing lipophilic drug solubility. As shown in Fig. 1, UA has a
carboxyl group that can act as a proton donor or acceptor, thus
allowing it to interact with the carboxyl group in Gelucire or
the hydroxyl groups in silicon dioxide. Such interactions
would be expected to shift or broaden the FTIR peaks
corresponding to the participating groups (2). Figure 2 shows
that intermolecular interactions took place between the drug
and the carriers in the SD, as shown by the progressive broad-
ening of the carbonyl band with increasing Gelucire content,
compared with the PM, in which the carbonyl bands remained
sharp.
Thermal analyses are important in SD characterization
because they provide important information regarding the
stability and storage of those systems. Such analyses may also
reveal the occurrence of possible incompatibilities between
the drug and the excipients or even changes in the solid-state
drug characteristics (29). Figure 4 shows the melting points of
Gelucire and UA (45°C and 280°C, respectively), which are
associated with their endotherms in the DSC analysis. More-
over, it is important to note an exothermic peak for pure UA
at approximately 200°C, which is characteristic of a crystalli-
zation event and could be associated with a polymorphic
conversion with temperature increase. This phenomenon is
similar to what has been observed with alprazolam in the
paper by De Armas and collaborators (30), who characterized
the polymorphisms in this drug through DSC.
Figure 4 shows that DSC experiments were not able to
distinguish SDs from PMs. Disappearance of the melting en-
dotherm of the drug in SDs and PMs that contain low drug
concentrations (5% or 10%) is evident, which is a commonly
observed finding. This phenomenon could be related to either
UA conversion from a crystalline to an amorphous structure
in SDs, dissolution of the drug in the molten carrier in both
SDs and PMs, or a combination of these two events (31).
Conversely, in systems containing larger drug amounts (50%
or 20%), it is possible to identify the UA melting endotherm
because it is present in excess. As a result, the drug either does
not solubilize completely in the molten polymer, or is not fully
converted to the amorphous form, and the excess drug is
deposited as crystals within the polymer matrix.
Hot stage microscopy experiments were conducted to
better understand how the drug is dispersed within the carrier,
what thermal events are associated with UA heating and to
visualize whether the drug dissolves in the molten polymer
after heating. After melting the Gelucire, the remaining UA
solid content partially dissolved in the molten mass, which
may explain the unobserved melting endotherm for the SDs
and the PMs containing 10% or 5% of the drug. The exother-
mic event at 200°C that was observed for UA in the DSC
experiments was also visualized by microscopy, which
revealed small needle-like crystals growing. A similar finding
has already been reported for carbamazepine, which was at-
tributed to polymorph conversion at high temperatures (32).
Importantly, this characteristic was preserved in the PMs, but
it was not observed for the SDs, which indicates that SD
formation altered the solid-state properties of UA. Further-
more, this may indicate that the SD technique changed the
drug state from crystalline to amorphous, which did not un-
dergo crystalline conversion at 200°C.
Another important tool for solid dispersion characteriza-
tion is the X-ray diffraction pattern, which shows the crystal-
line nature of the systems. Figure 5 reveals that the UA X-ray
peaks at 6°, 8°, and 15° are maintained in the PMs with
intensities that are directly proportional to the amount of drug
in the systems. However, these peaks are broadened and less
intense in SDs with higher drug concentrations and almost
disappear in the SD containing 5% drug. This observation
Fig. 8. Cellular viability in percentage of LLC-MK2 fibroblasts after
incubationwith different concentrations of PMandSD containing 5%UA
Table III. In Vitro Trypanocidal Activity of UA in PM and SD Against the Y Strain of T. cruzi
Product
% Lysis±SD/concentration (μM)
IC50 (μM)8 32 128 256
PM004 0±0 0.43±0.04 34.48±3.10 33.62±1.40 396.7
SD004 3.44±0.31 8.62±0.87 44.82±2.88 48.27±4.20 219.2
PM physical mixture, SD solid dispersion, IC50 inhibitory concentration
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could indicate conversion of UA crystals to an amorphous
structure in the SDs. This conversion may have been incom-
plete because of the presence of small remaining peaks; how-
ever, the decrease of the most intense UA peak at 15° is
evident in the SDs compared to the PMs. The observed con-
version from the crystalline to the amorphous form is com-
monly found in SDs prepared by solvent methods, and
Gelucire has been demonstrated to form SDs with drugs in
the amorphous state (7,10).
Figure 6 shows the better solubilization in SDs compared
with PMs, which was proportional to the Gelucire content. As
a surfactant, Gelucire forms micelles in aqueous media, caus-
ing lipophilic compound solubilization (6). Among other fac-
tors, the higher solubility values observed for the SDs may be
attributed to the conversion of UA from the crystalline to the
amorphous state, which may be more soluble because there is
no crystal lattice to be broken during dissolution studies,
making the process more energetically favorable (33).
The dissolution studies were carried out at sink condi-
tions by incorporating 1% sodium lauryl sulfate in phosphate
buffer at pH 6.8, which makes the dissolution experiment
more physiologically meaningful because of bile salt presence
in the gastrointestinal tract (34,35). From Fig. 7, it is evident
that dissolution of pure UA is very low, and it is not greatly
modified by formulation as a PM. Conversely, a dramatic
enhancement in the UA dissolution rate was observed for
the SDs, in which the drug and hydrophilic polymers are in
close contact. The products containing larger carrier amounts
presented higher dissolution profiles, as expected. Possible
mechanisms for the observed solubility improvements were
described by Ford (36) and include carrier solubilization
effects, aggregation absence, improved wettability, and drug
conversion to the amorphous state. Additionally, particle size
reduction plays an important role in solubility because of
increased contact area. As demonstrated in Table II, the prod-
uct SD004, which contained 5% drug, has a d90 particle size of
59.38 μm, smaller than pure UA.
The SD containing 5% drug, which had the highest
dissolution rate, and the PM containing the same drug
load were also analyzed after 6 months of room temper-
ature storage. Drug content determination (Table I) dem-
onstrated the chemical stability of UA because the SD
maintained 90.03% of the labeled UA content, which
was initially 91.16%. Additionally, physical stability was
demonstrated through an XRD assay, shown in Fig. 5.
The resulting data demonstrated that UA did not revert
to the crystalline state, a stability problem commonly
present in SDs, which can be avoided by surfactant car-
riers such as Gelucires (6). Together, these results help to
explain the maintenance of the SD dissolution profile
after the storage period (Fig. 7).
When investigating compounds with activity against Cha-
gas disease, it is critical to assess their therapeutic potential, as
evaluated by trypanocidal activity, and to verify a lack of
mammalian cytotoxicity. Thus, cytotoxicity studies using Rhe-
sus monkey kidney epithelial cells (LLC-MK2), a cellular
model for toxicity evaluation, were performed and demon-
strated that both PM004 and SD004 containing 5% UA are
safe at concentrations equivalent to 8, 32, 156, and 256 μM
because cellular viability was maintained at approximately
100% (Fig. 8). These products were also evaluated for their
trypanocidal activity in vitro (Table III), which revealed in-
creased lysis of T. cruzi trypomastigote forms, and conse-
quently, lower IC50 for SD compared to PM. These results
are in accordance with the higher dissolution and solubility
achieved with Gelucire-prepared SDs.
Despite enhanced UA dissolution in the SD that
contained 95% Gelucire and silicon dioxide, in vivo tests are
still needed to determine the effects of UA carried by SD in
Chagas disease treatment. Pharmacokinetic studies will also
need to be developed to investigate whether the SD enhances
UA oral bioavailability.
CONCLUSION
The results obtained in this study demonstrated improve-
ments in the solubility and dissolution of the lipophilic drug
ursolic acid in solid dispersions compared with physical mix-
tures, which was maintained after 6 months of room temper-
ature storage. This result could be attributed to improved
wettability, micellar solubilization caused by the lipid surfac-
tant Gelucire, conversion of ursolic acid from a crystalline to
an amorphous structure, or hydrogen bond formation be-
tween the carriers and drug. Taken together, these results
may explain the improved in vitro trypanocidal activity of
ursolic acid in solid dispersion compared to the physical mix-
ture, which were also demonstrated to be safe against mam-
malian fibroblast cells. Therefore, the results presented in this
work are promising for development of a dosage form con-
taining ursolic acid to treat Chagas disease.
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